Arlyn Valencia, MD
Neurology · Las Vegas, NVNPI 1841205523
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 925 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations.
Across 925 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Biogen$2K
- Novartis$2K
- Livanova USA, Inc.$1K
- Merz Pharmaceuticals, LLC$1K
- Sunovion Pharmaceuticals Inc.$813
- plus $10K from 54 others
What the payments were for
- Travel & lodging$6023%
- Food & beverage$17,20594%
- Education$4072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,264
- PURIFIED CORTROPHIN GEL$243
- KESIMPTA$237
- XEOMIN$225
- Prospera$131
- MAYZENT$120
How this compares
$18,214 in reported general payments places this provider in the 80th percentile of 145 neurology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 51 | $888,857 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 32 | $445,799 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 17 | $300,310 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 17 | $282,159 |
| Kesimpta PenOfatumumab | 20 | $166,467 |
| XeominIncobotulinumtoxina | 87 | $98,806 |
| Nurtec OdtRimegepant Sulfate | 52 | $55,113 |
| NuplazidPimavanserin Tartrate | 11 | $54,498 |
| BriviactBrivaracetam | 29 | $40,882 |
| AptiomEslicarbazepine Acetate | 11 | $35,002 |
| ValtocoDiazepam | 12 | $29,969 |
| UbrelvyUbrogepant | 18 | $28,025 |
| QuliptaAtogepant | 17 | $25,635 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $9,549 |
| AdlarityDonepezil Hcl | 20 | $8,896 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt | $315 | $943,970103 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $253 | $300,31017 claims |
| Merz North America, Inc.Xeomin | $304 | $98,80687 claims |
| Acadia Pharmaceuticals IncNuplazid | $490 | $54,49811 claims |
| AbbVieUbrelvy, Qulipta | $1,953 | $53,66035 claims |
| UCB, Inc.Briviact | $799 | $40,88229 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $813 | $35,00211 claims |
| Neurelis, Inc.Valtoco | $273 | $29,96912 claims |
| Corium, LLCAdlarity | $492 | $8,89620 claims |
| Upsher-smith Laboratories LLCTopiramate | $241 | $14026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 145 neurology providers in Nevada.
Other neurology in Las Vegas
- Zoltan MariLas Vegas$629K
- Fan ZhangLas Vegas$398K
- le HuaLas Vegas$385K
- Mehdi AnsariniaLas Vegas$306K
- Carrie HershLas Vegas$209K
- Shanker DixitLas Vegas$137K
- Charles KamenLas Vegas$124K
- Toya MaloneLas Vegas$123K
- Nicole TheuvenetLas Vegas$120K
- Kevin XieLas Vegas$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.